Baxter International Completes Its Mallinckrodt Assets Buy

Baxter International (BAX) announced the completion of its acquisition of Recothrom and Preveleak assets from Mallinckrodt Pharmaceuticals (MNK) for a total consideration of $185.0 million. This transaction includes $153.0 million in upfront payments and the rest in future milestone-based payments. Additionally, Baxter International has assumed Preveleak’s associated expenses and the contingent liabilities. Preveleak’s manufacturing operations are also included in the deal.